EU/3/11/898: Orphan designation for the treatment of chronic non-infectious uveitis



On 30 August 2011, orphan designation (EU/3/11/898) was granted by the European Commission to Santen Oy, Finland, for sirolimus for the treatment of chronic non-infectious uveitis.

Key facts

Active substance
Intended use
Treatment of chronic non-infectious uveitis
Orphan designation status
EU designation number
Date of designation
Santen Oy
Niittyhaankatu 20
FI-33720 Tampere
Telephone: + 358 3 284 8111
Telefax: + 358 3 318 19 00

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Update history

Date Update
August 2022 Please note that this product was withdrawn from the Union Register of orphan medicinal products in August 2022 on request of the Sponsor.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

Related content

How useful was this page?

Add your rating